Key Highlights

  • Revenue growth: Amgen reported double-digit Revenue growth earlier in 2026 and lifted its full-year outlook after a strong quarter.
  • Pipeline priority: MariTide, an experimental monthly obesity injection, is Amgen's strategic priority, positioned against weekly rivals.
  • Portfolio funding: Established, high-margin drugs generate substantial cash that Amgen reinvests in research and pipeline-refilling acquisitions.
  • Patent risk: Amgen faces Patent expirations on some existing products, inviting cheaper competition and pressuring future growth.

Amgen's (NASDAQ:AMGN) next chapter will be written by its pipeline, and one experimental medicine in particular has captured investors' attention: a monthly obesity injection that could let the company compete in one of the fastest-growing markets in healthcare. For Nasdaq 100 investors, Amgen is a reminder that the index contains not only technology but the biotechnology firms whose fortunes hinge on the success of individual drugs.

What Amgen Does

Amgen is one of the world's largest biotechnology companies, developing and Manufacturing medicines for serious illnesses including cancer, heart disease, inflammatory conditions and rare diseases. It sits in the healthcare sector. Its Business rests on a portfolio of established, high-margin drugs that generate substantial cash, which it reinvests in research and in acquisitions to refill its pipeline as older products face competition from cheaper copies.

The Pipeline in Focus

The centrepiece of the current story is MariTide, an experimental obesity treatment that Amgen is positioning as a potential best-in-class monthly injection, in contrast to weekly rivals. The company has advanced it through clinical testing and made it a strategic priority, even discontinuing an earlier-stage obesity asset to concentrate its efforts. Meanwhile the existing business has been growing, with Amgen reporting double-digit revenue growth earlier in 2026 and lifting its full-year outlook after a strong quarter. The combination matters: reliable current profits fund the ambitious bets, while the pipeline determines whether growth accelerates or fades as older drugs lose protection.

Why it Matters for the Nasdaq 100

Amgen offers the index exposure to healthcare, a sector whose Demand is relatively insulated from economic cycles. Its push into obesity treatment connects it to one of the most closely watched themes in medicine, where the market opportunity is enormous. As a large, dividend-paying member of the benchmark, Amgen also provides Diversification away from technology, and its results are a useful read on the health of the biotechnology industry and its appetite for innovation.

The Risks to Weigh

Drug development is inherently risky: promising candidates can Fail in late-stage trials, and even approved drugs must win Market Share against entrenched competitors. The obesity market, though large, is crowded and dominated by established players, so success is far from guaranteed. Amgen faces patent expirations on some existing products, which invite cheaper competition. Pricing pressure and regulation add uncertainty, and its debt, partly from acquisitions, must be serviced. A single trial setback can move the shares sharply.

Old Drugs, New Bets

Amgen embodies a tension that runs through the whole pharmaceutical industry: the need to fund tomorrow's breakthroughs with yesterday's successes. Its established medicines generate substantial cash, but many face the eventual loss of patent protection, after which cheaper copies erode their sales. To keep growing, Amgen must continually replenish its pipeline, either through its own research or by acquiring promising companies, and its large push into obesity treatment is the most visible example of that effort. The stakes are high because the obesity market is enormous, but the competition is formidable and already well established. Success would transform Amgen's growth prospects; failure would leave it more reliant on ageing products and searching for the next big bet, which is why the pipeline commands such attention.

What to Watch Next

Readers should follow clinical trial results and regulatory milestones for MariTide, since these will largely determine the growth outlook, and watch how Amgen positions it against rivals on dosing and tolerability. The performance of the existing portfolio matters, because it funds the pipeline and cushions patent losses. Commentary on new acquisitions signals how Amgen intends to sustain growth. Finally, watch the Balance Sheet and dividend, because Amgen's appeal combines the promise of pipeline breakthroughs with the reassurance of steady cash returns, and investors will want confidence that the bets do not undermine financial discipline.

Funding Tomorrow's Bets With Today's Drugs

Amgen's next chapter depends on a familiar industry tension: funding tomorrow's breakthroughs with today's aging, still-profitable drugs. Its push into obesity treatment carries the potential to transform its growth trajectory, but the same pipeline that could deliver a breakthrough could just as easily disappoint, which is why every clinical and regulatory update draws such close scrutiny from investors.